Evelyne Minucchi

Ms. Evelyne Minucchi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BRBartolo Rizzo
Bartolo Rizzo
FDFrancesca Dragoni
Francesca Dragoni
MDMaria Irene Dainesi
Maria Irene Dainesi
RGRosalinda Di Gerlando
Rosalinda Di Gerlando
EMEvelyne Minucchi
Evelyne Minucchi
SGStella Gagliardi
Stella Gagliardi
The complexity of RNA metabolism has become crucial in neuromuscular diseases, especially for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Our goal was to search for possible pathways that differ between the two diseases, in which DMD develops a severe phenotype compared to BMD. In this work, we aimed to evaluate the transcriptomic profile in skeletal muscle biopsies derived from patients with either DMD or BMD. We collected RNA obtained from pediatric patients with DMD (n = 12) and with BMD (n = 6). Compared to patients with BMD, patients with DMD showed a particular activation of genes involved in collagen synthesis, extracellular matrix organization, and Oncostatin M-dependent pathways, important for fibrotic processes. This suggests that a more severe phenotype in patients with DMD compared to those with BMD may be due to greater deregulation of these pathways, reflecting the clinical picture of patients observed. Our results allowed us to highlight the molecular differences between the two phenotypic groups, shedding light on the pathways that make Duchenne dystrophy more severe than its counterpart does. This study provides preliminary insights into the difference in gene expression between the two groups and lays the basis for the identification of possible mechanisms that differentiate between the two diseases.

Verified
Journal Article
Open access
PDF file
BRBartolo Rizzo
Bartolo Rizzo
MRMichele Rossi
Michele Rossi
RFRiccardo Rocco Ferrari
Riccardo Rocco Ferrari
EPElisa Pellegrini
Elisa Pellegrini
FDFrancesca Dragoni
Francesca Dragoni
ADANNALISA DAVIN
ANNALISA DAVIN
Alzheimer’s disease (AD), the leading cause of dementia, is expected to markedly increase in prevalence in the coming decades. Beyond amyloid and tau pathologies, accumulating evidence suggests that mitochondrial dysfunction and impaired protein homeostasis play crucial roles in AD onset and progression. Building on our previous identification of molecular signatures associated with disease progression, this study investigated whether epigenetic alterations of mitochondrial DNA (mtDNA) contribute to cognitive decline. Specifically, we analyzed the methylation status of the mtDNA regulatory D-loop region and mtDNA copy number in blood-derived DNA samples from 75 participants who we followed longitudinally over eight years. Subjects were classified into four groups according to clinical progression from healthy cognition to mild cognitive impairment (MCI) and AD. Using a linear mixed-effects model, we observed significant differences in methylation dynamics and mtDNA copy number across groups and time points. Healthy controls showed a progressive increase in D-loop methylation, whereas individuals converting to AD exhibited a marked decrease in its level. An opposite trend was evidenced for mtDNA copy number. These findings suggest that reduced D-loop methylation and increased mtDNA are associated with mitochondrial dysfunction and disease progression, whereas increased methylation may represent a possible protective mechanism.

Verified
Journal Article
Open access
PDF file
RGRosalinda Di Gerlando
Rosalinda Di Gerlando
FDFrancesca Dragoni
Francesca Dragoni
EMEvelyne Minucchi
Evelyne Minucchi
MGMaria Garofalo
Maria Garofalo
GPGiulia Perini
Giulia Perini
SGStella Gagliardi
Stella Gagliardi
Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD) are complex neurodegenerative disorders, often sharing overlapping symptoms. Non-coding RNAs may be involved in pathological processes in these conditions, hence the study of miRNAs isolated from plasma-derived extracellular vesicles (EVs) could provide exploratory insights into the molecular background. The main aim of this work was to identify shared deregulated miRNAs presenting different expression patterns in the two pathologies. A selection of the identified deregulated miRNAs was further studied with the purpose of identifying their mRNA targets and generating hypotheses on their potential pathological involvement. A total of 340 and 291 differentially expressed miRNAs were found in FTD and AD, respectively. Among the commonly deregulated miRNAs with opposite expression patterns between the two conditions, miR-638 emerged as a candidate of interest, showing consistent patterns across our experimental analyses. Nevertheless, these findings are preliminary and intended to be interpreted cautiously, requiring validation in larger cohorts. In addition, the expression of two of its predicted targets in peripheral blood mononuclear cells (PBMCs) appeared to align with miR-638 expression in the same cell type and may reflect potential differences in underlying brain pathological states.

23 October 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
EMEvelyne Minucchi
Evelyne Minucchi
RGRosalinda Di Gerlando
Rosalinda Di Gerlando
FDFrancesca Dragoni
Francesca Dragoni
CICamillo Imbimbo
Camillo Imbimbo
EZElisabetta Zardini
Elisabetta Zardini
SGStella Gagliardi
Stella Gagliardi
Background: Plasma phosphorylated tau 217 (pTau217) has emerged as one of the most accurate biomarkers for Alzheimer's disease (AD). However, direct comparisons of pTau217 levels between different automated immunoassays remain limited. Objective: In this context, our work aimed to compare Lumipulse and Ella platforms for the measurement of plasma pTau217 across the AD continuum. Methods: Blood samples were collected from 32 subjective cognitive decline (SCD), 25 mild cognitive impairment (MCI), and 10 Alzheimer's disease (AD) patients. Plasma pTau217 levels were assessed using Lumipulse G600II automated system and Ella immunoassay SR-X platform. Associations with clinical variables and agreement between platforms were assessed. Results: Plasma pTau217 levels increased from SCD to AD with both assays. Lumipulse showed a significant difference between SCD and AD (p = 0.0011), while Ella detected differences between SCD and MCI (p = 0.0198) and SCD and AD (p = 0.0001). Both assays showed a significant inverse correlation with Mini-Mental State Examination (Lumipulse: r = −0.4913; p = 0.0001. Ella: Pearson r = −0.5139; p = 0.0001). A moderate correlation between platforms was observed. Bland–Altman analysis revealed a negative bias, with Lumipulse yielding lower values than Ella and increasing variability at higher concentrations. Conclusions: Lumipulse and Ella provided consistent qualitative information on plasma pTau217 across the AD continuum and show similar associations with cognitive performance, meaning that they are both comparable techniques. However, systematic bias and proportional variability limit their quantitative interchangeability, highlighting the need for cross-platform standardization.

13 August 2026 in Genes
Verified
Journal Article
Open access
PDF file
EMEvelyne Minucchi
Evelyne Minucchi
FDFrancesca Dragoni
Francesca Dragoni
RGRosalinda Di Gerlando
Rosalinda Di Gerlando
GPGaia Pavanello
Gaia Pavanello
MRMatteo Cotta Ramusino
Matteo Cotta Ramusino
SGStella Gagliardi
Stella Gagliardi
Background: Frontotemporal dementia (FTD) is a neurodegenerative disease that shares numerous clinical features with other forms of dementia. In this context, non-coding RNAs, specifically microRNAs (miRNAs), represent a promising tool for differential diagnosis. Since these miRNAs can be isolated from circulating extracellular vesicles (EVs) in peripheral blood, they provide a direct insight into FTD-specific molecular processes. Consequently, while EV-contained miRNAs hold potential as disease-specific biomarkers, investigating their relative target genes can help elucidate their precise functional roles. Aim: This work aimed to identify a specific miRNA signature to better characterize FTD pathology. Methods: Building on a previous Next-Generation Sequencing (NGS) analysis, three candidate miRNAs were selected for validation in both EVs and peripheral blood mononuclear cells (PBMCs) of FTD patients. Subsequently, the predicted target genes of two of these miRNAs were validated in PBMCs to assess their expression levels. Results: Our findings revealed that miR-365a-3p and miR-212 were significantly down-regulated in FTD. Conclusions: Together with their target genes, these miRNAs are involved in cell cycle and apoptotic pathways, suggesting a potential role in the pathological mechanisms of the disease.